Nivolumab for metastatic renal cell carcinoma:Results of a randomized phaseⅡtrial. Motzer RJ,Rini BI,Mc Dermott DF,et al. Journal of Clinical Oncology . 2015Motzer ILl, Rini BI, Mcdermott DF, et al. Nivolumab for Meta- static Renal Cell Carcinoma: Results of a Randomized...
“There remains a significant unmet medical need for advanced renal cell carcinoma patients who have received prior therapy and are often repeatedly treated with agents that are similar in mechanism," Michael Giordano, MD, senior vice president, head of Oncology Development, Bristol-Myers Squibb, sai...
OPDIVO®(nivolumab) is a prescription medicine used in combination with YERVOY®(ipilimumab) to treat adults with kidney cancer in certain people when your cancer has spread (advanced renal cell carcinoma) and you have not already had treatment for your advanced RCC. ...
We evaluated the cost-effectiveness of nivolumab versus everolimus in patients with advanced renal cell carcinoma (RCC) from a US payer perspective. A partitioned survival model consisting of three health states, progression-free survival (PFS), progress
The U.S. Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo, Bristol-Myers Squibb) and cabozantinib (Cabometyx, Exelixis) as first-line treatment for patients with advanced renal cell carcinoma (RCC). Efficacy was evaluated in CHECKMATE-9ER (...
For certain adults with advanced kidney cancer (renal cell carcinoma) OPDIVO®(nivolumab) is a prescription medicine used in combination with YERVOY®(ipilimumab) to treat adults with kidney cancer in certain people when your cancer has spread (advanced renal cell carcinoma) and you have not al...
Neoadjuvant nivolumab (Opdivo; Bristol Myers Squibb), an immune checkpoint inhibitor (ICI), prior to nephrectomy may improve survival outcomes in patients with high-risk and non-metastatic clear cell renal cell carcinoma (ccRCC), according to authors who published findings from a phase...
Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma BACKGROUND: In recent years, new drugs have been introduced for second-line treatment of advanced renal cell carcinoma (RCC). Nivolumab increases overall s... M Sarfaty,M Leshno,N Gordon,... - 《European Urology》 被引量: 7发...
Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with advanced renal cell cancer who have already undergone prior therapy. In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined whethe...
Nivolumabis anIgG4monoclonal antibodydeveloped by Bristol-Squibb that can block the binding of PD-L1 on tumor cells to PD-1 onT cells. Nivolumab restores the antitumor effect mediated by T cells[36]. Nivolumab is available forrenal cell carcinoma,Hodgkin lymphoma, and head and necksquamous cell...